Nine Masts Capital’s PDS Biotechnology PDSB Stock Holding History

Nine Masts Capital’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-67,507	Closed	-$40.8K	–	263
2026 Q1	$40.8K	Buy	+67,507	New	+$50.8K	0.01%	176

Other funds holding PDSB

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

MCM

Militia Capital Management Austin, Texas $3.37B AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Nine Masts Capital's PDSB Position: Q2 2026 in Review

Nine Masts Capital sold out of PDS Biotechnology (PDSB) in Q2 2026, closing a stake of 67,507 shares — an estimated $40.8K sold.

Nine Masts Capital first reported a position in PDSB in Q1 2026 and held it in 1 quarter. The position peaked at $40.8K in Q1 2026. 52 funds tracked by Wall St. Rank hold PDSB as of Q2 2026.

Nine Masts Capital reported no remaining PDS Biotechnology position as of Q2 2026 after selling out during the quarter.
Nine Masts Capital sold 67,507 PDS Biotechnology shares in Q2 2026, an estimated $40.8K.
Nine Masts Capital first reported a position in PDS Biotechnology in Q1 2026 and held it in 1 quarter.
Nine Masts Capital's PDS Biotechnology position peaked at $40.8K in Q1 2026.
52 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.